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Abstract
Introduction The natural product eupatorin has been reported
to have antiproliferative activity in tumour cell lines, but the exact
mechanism is unclear. The cytochromes P450 CYP1B1,
CYP1A1, and CYP1A2 have been shown to participate in the
activation of various xenobiotics, compounds derived from the
diet as well as chemotherapeutic drugs. CYP1B1 and CYP1A1
have also been proposed as targets for cancer chemotherapy
for their differential and selective overexpression in tumour cells.
In this study, we aimed to identify a possible mechanism of
action for the antiproliferative effect of eupatorin, which can be
attributed to CYP1 family-mediated metabolism.
Methods The study focuses on the antiproliferative action of
eupatorin on the human breast carcinoma cell line MDA-MB-
468 and on a cell line derived from normal mammary tissue,
MCF-10A. The cytotoxicity of the flavone, its effect on the cell
cycle of the abovementioned cell lines, and its metabolism by
CYP1 family enzymes were examined.
Results Eupatorin showed a dose-dependent inhibitory effect of
cell growth on MDA-MB-468 cells with a submicromolar median
inhibition concentration (IC50) whereas the IC50 of this
compound in MCF-10A cells was considerably higher. The
antiproliferative effect, as measured by EROD (ethoxyresorufin-
O-deethylase) assay and Western immunoblotting, was
attributed mainly to CYP1A1 expression in MDA-MB-468 cells
but not in MCF-10A cells. Moreover, CYP1 family enzymes were
shown to metabolise eupatorin in vitro to the flavone cirsiliol and
two other unidentified metabolites. Metabolism of eupatorin was
also detected in MDA-MB-468 cell cultures, whereas
metabolism by MCF-10A cells was negligible. Eupatorin was
further shown to arrest the cell cycle of the CYP1-expressing
cell line MDA-MB-468 in G2/M phase, whereas no effect was
observed in MCF-10A cells, which do not express CYP1
enzymes. The effect of eupatorin on the MDA-MB-468 cell cycle
could be reversed by co-application of the CYP1 inhibitor
acacetin.
Conclusion The flavone eupatorin is selectively activated in
breast cancer cells, but not in normal breast cells, due to CYP1
family metabolism. This provides a basis for selectivity which is
desired against breast tumour cells. In this sense, eupatorin is
shown by this study to be a very promising chemopreventative
candidate that should be examined further in an in vivo study.
Introduction
Breast cancer is the most common cancer and the second
leading cause of cancer-related death for women in the US
[1]. Current chemotherapeutic options for breast cancer
include drugs such as tamoxifen and the cytotoxics paclitaxel
and docetaxel, all of which show severe side effects [2]. There-
fore, there is a focus toward new chemotherapeutic and che-
mopreventative agents that show limited toxicity to normal
tissue and possess a more favourable therapeutic window.
Natural product research has revealed a large variety of phyto-
chemicals that have been proven successful against breast
cancer in several epidemiological and in vitro studies. In par-
ticular, the class of flavonoids has been well established as aPage 1 of 12
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Compounds such as the isoflavone genistein have shown
promise in the prevention of breast cancer worldwide [3,4].
Eupatorin is a flavone which is found in various medicinal
plants. It is present in Orthosiphon stamineus, a plant widely
used in southeast Asia for the treatment of various diseases
[5], in the leaves of Lantana montevidensis (Spreng.) Briq.
(Verbenaceae), which is indigenous to tropical regions of the
Americas and has been used in folk medicine for the treatment
of bronchitis and stomach disorders [6], and in the aerial
plants of Tanacetum vulgare, a medicinal plant found in South
America [7]. Eupatorin has been shown to have anti-inflamma-
tory effects in a mouse ear oedema model [7] as well as anti-
proliferative activity in human gastric adenocarcinoma (MK-1),
human uterus carcinoma (HeLa), and murine melanoma
(B16F10) cell lines [6]. In addition, it has demonstrated cyto-
toxic activity toward highly metastatic murine colon carcinoma
(26-L5) cells [5]. However, none of the above studies has pro-
posed a plausible mechanism of action for the antiproliferative
or cytotoxic activity of eupatorin.
The cytochromes P450 are enzymes that catalyse the meta-
bolic activation of various xenobiotics. The cytochromes P450
CYP1B1 and CYP1A1 are differentially expressed within the
tumour microenvironment compared with the surrounding nor-
mal tissue and have been proposed as targets for novel chem-
otherapeutic agents. The enzymes may catalyse the
conversion of prodrugs that are non-toxic to normal cells but
are activated to cytotoxic agents in the tumour site [8,9].
CYP1A1 has been shown to be overexpressed in ovarian can-
cer cells and esophageal tumours, as opposed to normal cells
and tissue [10-12], and CYP1B1 protein has been detected
in a wide variety of tumours such as breast, brain, colon, and
lung, whereas no protein was detected in corresponding nor-
mal samples [13]. The natural product resveratrol, which has a
structure similar to eupatorin, and the synthetic compounds
Phortress and AQ4N are all prodrugs, which are metabolised
by CYP1A1 and CYP1B1 to antiproliferative and more active
agents [14-16]. The third member of the CYP1 family,
CYP1A2, has also been shown to participate in the activation
of chemotherapeutic drugs in addition to natural products
[17,18]. We therefore undertook a detailed study of the
metabolism of the natural flavone eupatorin by CYP1 enzymes
in vitro and in human breast cancer cells.
A novel mechanism for the antiproliferative action of eupatorin
is proposed. The flavone is considered a CYP1A- and
CYP1B1-activated prodrug that has cytostatic effects in
MDA-MB-468 breast adenocarcinoma cells upon CYP1-
mediated metabolism. No cytostatic effects are found in MCF-
10A normal breast cells, which do not express CYP1A and
CYP1B1. Eupatorin is a natural product that is shown at least
in in vitro assays to be a potential chemopreventive agent and
provides the desired selectivity between cancer and normal




Eupatorin and cirsiliol were purchased from Lancaster (Hey-
sham, Lancashire, UK). Acacetin, nicotinamide adenine dinu-
cleotide phosphate (NADPH), salicylamide, propidium iodide
(PI), and phosphate-buffered saline (PBS) were purchased
from Sigma-Aldrich (Poole, Dorset, UK), and high-pressure liq-
uid chromatography (HPLC)-grade acetonitrile and methanol
were purchased from Fisher Scientific (Loughborough,
Leicestershire, UK). Media and cell culture reagents were from
Sigma-Aldrich. Western blotting kits, sample buffer, molecular
weight marker, nitrocellulose membrane, and filter paper for
Western blotting were obtained from Bio-Rad Laboratories
(Corston, Bath, UK). Polyvinylidene fluoride (PVDF) membrane
was purchased from Sigma-Aldrich. The primary antibodies to
detect CYP1A (both CYP1A1 and CYP1A2) and CYP1B1
were obtained from Gentest Corporation (now part of BD Bio-
sciences, San Jose, CA, USA), via BD Biosciences (Cowley,
Oxford, UK), and Auvation Limited (Aberdeen, Scotland, UK),
respectively. Cell culture media and other ingredients used in
lysis buffer in Western blotting, including secondary antibod-
ies, were supplied by Sigma-Aldrich. ECL (enhanced electro-
chemiluminescence) Plus™ reagent, PVDF membrane, and
film used in Western blotting were obtained from Amersham
Biosciences (now part of GE Healthcare, Little Chalfont,
Buckinghamshire, UK). Microsomes containing human cyto-
chrome P450 (CYP1A1 or CYP1B1) and human NADPH-
cytochrome P450 reductase (SUPERSOMES™), prepared
from recombinant baculovirus-transformed insect cells, were
obtained from BD Biosciences. Control microsomes prepared
from insect cells treated with the vector plasmid were also
obtained from BD Biosciences.
Ethical approval
In the UK, by virtue of section 54(7) of the Human Tissue Act,
cell lines are not legally regarded as coming from a human
body. As such, the experimental use of MDA-MB-468 and
MCF-10A cells does not require ethical approval.
Cell culture
MDA-MB-468 cells were maintained in RPMI-1640 medium
without phenol red with 10% foetal calf serum and 2 mM
glutamine. MCF-10A cells were maintained in Dulbecco's
modified Eagle's medium/Ham's F-12 medium (1:1) with 10%
foetal calf serum, 2 mM glutamine, insulin (10 μg/mL), hydro-
cortisone (500 ng/mL), and epidermal growth factor (20 ng/
mL). Cells were passaged every 2 to 3 days using trypsin
EDTA (ethylenediaminetetraacetic acid).
Ethoxyresorufin-O-deethylase assay in cells
MDA-MB-468 and MCF-10A cells (5 × 104 cells per millilitre)
were grown in 24-well plates for 48 hours. ThePage 2 of 12
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as described previously [19]. The cells were washed once
with PBS, and fresh medium containing salicylamide to inhibit
conjugating enzymes (1.5 mM) was added to the wells. The
plate was left in the incubator at 37°C for 5 minutes, and 7-
ethoxyresorufin was added at a final concentration of 5 μM.
The reaction was carried out for 1 hour at 37°C with gentle
stirring of the plate every 5 minutes. Aliquots (200 μL) were
transferred to Eppendorf tubes and the reaction was termi-
nated by the addition of an equal volume of ice-cold methanol,
which results in immediate cell lysis. Then, the samples were
centrifuged at 3,000 rpm for 10 minutes and the supernatants
transferred to a 96-well plate and read using a Spectra Max
M5/M5e microplate reader (Molecular Devices Corporation,
Sunnyvale, CA, USA) with excitation and emission at 530 and
590 nm, respectively. Standard curves for resorufin formation
were also performed.
Western immunoblotting
MDA-MB-468 and MCF-10A cells were trypsinised and
resuspended in 200 μL of lysis solution (Sigma-Aldrich) con-
taining protease inhibitor cocktail (Sigma-Aldrich) and DTT
(dithiothreitol) (1 mM). Twenty microlitres of each sample was
mixed with SDS-PAGE Laemmli buffer (containing 5% mer-
captoethanol) in 1:1 ratio. The samples were heated at 100°C
for 4 to 5 minutes and then each sample was loaded to acry-
lamide gels (10% acrylamide for resolving gel and 5% acryla-
mide for stacking gel) at the required volume to obtain 15 μg
of protein for detection of CYP1A1 or 20 μg of protein for
detection of CYP1B1. Wet blotting was used to transfer the
protein from the gel to the membrane. For CYP1A detection,
nitrocellulose membrane was used, whereas PVDF membrane
was used for CYP1B1 detection. The membrane was incu-
bated with 10% milk in 0.05% tris-buffered saline Tween-20
(TBST) at room temperature for 1 hour on the shaker in order
to block non-specific binding. Primary antibody was diluted in
5% milk in 0.05% TBST and incubated at 4°C overnight with
the membrane. The membrane was then washed six times for
15 minutes each time with 0.05% TBST to rinse out the
excess primary antibody and incubated with secondary anti-
body diluted in 5% milk in 0.05% TBST at room temperature
for 1.5 hours. The excess secondary antibody was washed six
times with 0.05% TBST as before and the membrane was
exposed to ECL Plus™ reagents. Finally, the signal was trans-
ferred to a film that was developed in the dark.
MTT assay
MDA-MB-468 or MCF-10A cells were plated at a density of
104 cells per millilitre in 96-well flat-bottomed plates. After 24
hours, the medium was carefully aspirated and eupatorin was
added in quadruplicate in 200 μL of medium to give a final
concentration of not more than 0.1% (vol/vol) dimethylsulfox-
ide (DMSO). The cells were then allowed to grow for 96 hours
at 37°C. The medium was removed and fresh medium with
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) (0.4 mg/mL) was added to each well for 3 hours. All
medium was aspirated and the formazan product generated by
viable cells was solubilised with 150 μL of DMSO. Plates were
vortexed and the absorbance at 540 nm determined using a
Spectra Max M5/M5e microplate reader. Results were
expressed as the percentage of proliferation compared to con-
trols containing 0.1% DMSO. The median inhibition concen-
tration (IC50) was calculated using GraphPad Prism software
(GraphPad Software, San Diego, CA, USA). The dose range
generally was in half-log dilutions (for example, 100, 30, 10, 3,
1, 0.3, 0.1, 0.03, 0.01, 0.003, and 0.001 μM). For inhibition
studies, acacetin was added to a final concentration of 1.5 μM
in 200 μL of medium along with eupatorin.
Enzyme assay and high-pressure liquid chromatography 
analysis
Incubations (100 μL) contained NADPH (0.5 mM), MgCl2 (0.5
mM), phosphate buffer (20 mM), and eupatorin (10 μM). The
reaction was initiated with the addition of recombinant micro-
somes expressing CYP1A1 or CYP1B1 (20 pmol/mL of
human cytochrome P450) at 37°C and was carried out for 20
minutes. Samples were taken every 5 minutes and each reac-
tion was terminated by the addition of 100 μL of 1% acetic
acid in methanol. A centrifugation step at 3,500 g for 20 min-
utes at 4°C ensured that the protein was removed from each
sample and the supernatants were analysed by a reversed-
phase PerkinElmer 200 HPLC (PerkinElmer, Waltham, MA,
USA). For co-elution studies, a 20-minute CYP incubate of
eupatorin was prepared as above and spiked with an authentic
standard of the putative metabolite. The resulting sample was
analysed by HPLC and compared with a control with no
metabolite standard.
A Luna 5 μC18, 4.6 × 150 mm column (Phenomenex, Maccles-
field, Cheshire, UK) was used. The mobile phase consisted of
solvent A and solvent B. Solvent A contained 1% acetonitrile
and 0.5% acetic acid in water, and solvent B contained 4%
acetonitrile and 0.5% acetic acid in methanol. A gradient pro-
gram was used starting with 60% solvent A and 40% solvent
B at time 0 and ending with 10% solvent A and 90% solvent
B after 10 minutes. The final conditions were held for 1 minute
before returning to initial solvent conditions, and 8 minutes
were allowed for column equilibration between each run.
Eupatorin and its metabolites were monitored by a Waters
200 UV detector (Waters, Watford, Hertfordshire, UK) at 350
nm. The flow rate was 1 mL/minute and the temperature was
37°C.
Metabolism in cells
MDA-MB-468 or MCF-10A cells (2 × 104 cells per millilitre)
were plated in 24-well flat-bottomed plates and left to grow for
48 hours. All media were removed and the cells were washed
once with PBS. Eupatorin was added in 200 μL of medium at
a final concentration of 10 μM and salicylamide at a final con-
centration of 1.5 mM. The cells were incubated at 37°C for 45Page 3 of 12
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with 1% acetic acid in methanol. Lysis buffer (200 μL) pur-
chased from Sigma-Aldrich was added to each of the wells
and the cells were lysed by continuous pipetting. One percent
acetic acid in methanol (200 μL) was added to the cell lysates.
Both cell and medium samples were centrifuged for 15 min-
utes at 13,000 rpm and finally analysed with HPLC. Protein
concentration was estimated by the Bradford assay to be 0.5
mg/mL in each sample [20].
Flow cytometry
MDA-MB-468 or MCF-10A cells were pretreated with eupa-
torin or cirsiliol or 0.1% DMSO (negative control) for 30 or 48
hours. The medium was aspirated, and the cells were washed
with cold PBS, fixed in 70% ethanol, and stored at least 2
hours at -20°C. The cells were then resuspended in PI solution
(70 μg/mL in PBS) containing 13 Kunitz units of RNase and
incubated at 37°C for 30 minutes. Fluorescence was meas-
ured on a fluorescence-activated cell sorter flow cytometer
(Beckman Coulter, Oakley Court, Buckinghamshire, UK). The
machine was calibrated and the laser aligned using fluores-
cent beads and a flow-check protocol before each sample
was run. All photomultiplier tubes should give a half-coefficient
of variance of less than 2.5 in the calibration. All of the param-
eters required for the DNA analysis protocol, which included
voltage, peak gain, integrated gain, and discriminator, were
optimised in preliminary experiments. Doublets were sepa-
rated from single cells in G2/M phase by gating. The data
obtained from each histogram were then analysed using Mul-
ticycle Analysis 2.0 software (Phoenix Flow Systems, San
Diego, CA, USA) and compared with manual estimation of the
proportion of cells in each phase. Apoptosis was measured by
the proportion of cells present in the sub-G1 phase.
Statistical analysis
Results are expressed as mean ± standard deviation for at
least three independent experiments, unless indicated
otherwise.
Results
Eupatorin reversibly inhibits proliferation of MDA-MB-
468 cells while having minor effects on MCF-10A cells
MDA-MB-468 and MCF-10A cells were treated with eupatorin
for 96 hours and cell viability was measured using the MTT
assay. MCF-10A is a normal breast cell line that was used as
a comparison. Eupatorin had submicromolar toxicity in MDA-
MB-468 cells (IC50 0.5 μM), whereas it was considerably less
active in MCF-10A cells (IC50 50 μM) (Figure 1a). To identify
whether this effect was due to CYP1 enzyme-mediated
metabolism, eupatorin was co-incubated with the CYP1 inhib-
itor acacetin [21] and MTT assay was carried out as described
before. Treatment of MDA-MB-468 cells with both eupatorin
and acacetin reversed the cytotoxicity seen when eupatorin
was incubated with the cells alone (Figure 1b). When acacetin
was added along with eupatorin to MDA-MB-468 cells, a dra-
Figure 1
MTT cell proliferation assays. (a) Cytotoxicity of eupatorin in MDA-MB-
468 cells and MCF-10A cells. (b) Decrease of eupatorin cytotoxicity in 
MDA-MB-468 cells after addition of acacetin. (c) Cytotoxicity of acace-
tin in MDA-MB-468 cells and MCF-10A cells. (d) Cytotoxicity of cirsiliol 
in MDA-MB-468 cells and MCF-10A cells. Cells were plated into 96-
well plates and treated with 10-3 to 100 μM eupatorin, acacetin, or cirsi-
liol (as described in Materials and methods) and allowed to grow for 96 
hours. For the inhibition experiment, acacetin was used at a final con-
centration of 1.5 μM. Error bars represent mean ± standard deviation 
(SD) for n = 4 determinations. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide.Page 4 of 12
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Acacetin on its own had no effect on cell proliferation (Figure
1c) at the concentration used (1.5 μM). Finally, we examined
the antiproliferative effect of the putative eupatorin-CYP1
metabolite cirsiliol and found a profile similar to that of eupa-
torin. Although cirsiliol was somewhat less potent in MDA-MB-
468 cells (IC50 2 μM) (Figure 1d), it inhibited MCF-10A prolif-
eration slightly stronger than eupatorin did (IC50 15 μM) (Fig-
ure 1d).
CYP1A1 and CYP1B1 proteins are expressed in MDA-
MB-468 breast cancer cells
To further support the finding that CYP1 family enzymes are
responsible for the bioactivation of eupatorin in MDA-MB-468
and not in MCF-10A cells, the two cell lines were examined for
their capacity to express CYP1 family enzymes. CYP1 family
enzyme activity was measured in MDA-MB-468 breast cancer
and MCF-10A normal breast cells with the EROD assay. The
cells were treated with 7-ethoxyresorufin and the amount of
resorufin produced was measured by fluorescence. MDA-MB-
468 cells clearly expressed active CYP1 family enzymes,
whereas very little expression was measured in MCF-10A cells
(Figure 2a). Even though the EROD assay is indicative of
CYP1A1 activity, it is not specific for any CYP1 enzyme. Thus,
Western immunoblotting was employed to provide more infor-
mation on the CYP1 expression profile of the two cell lines.
When the cells were probed with anti-CYP1A1 antibody,
MDA-MB-468 cells were shown to express CYP1A1 whereas
this protein could not be detected in MCF-10A cells (Figure
2b). A further attempt to examine CYP1B1 protein expression
in these two cell lines using an anti-rabbit CYP1B1 antibody
revealed a less intense signal of this protein in MDA-MB-468
cells compared with CYP1A1, whereas in MCF-10A cells no
CYP1B1 expression was detected (Figure 2b). The expres-
sion of CYP1A1 and CYP1B1 proteins was also inducible as
treatment with the dioxin TCDD (2,3,7,8-tetrachlorodibenzo-p-
dioxin) resulted in the upregulation of these two proteins in
MDA-MB-468 cells (Figure 2b). The signal for CYP1A1 was
stronger than the one observed in the untreated cells and
comparable to that of the microsome standard used (Figure
2b). Similarly, CYP1B1 protein level in MDA-MB-468 cells
increased after treatment with TCDD, although the signal was
considerably less than that of the CYP1B1- and the CYP1A1
microsome standards used. Thus, the breast carcinoma cell
line MDA-MB-468 constitutively expresses CYP1A1 and, after
induction, increases CYP1A1 levels and expresses low levels
of CYP1B1.
Eupatorin is metabolised to cirsiliol in microsomes 
expressing human CYP1 family enzymes and in MDA-
MB-468 cells
Following the first line of evidence that eupatorin is a substrate
for CYP1 family enzymes, we investigated the metabolism of
this natural product in microsomes expressing human CYP1
family enzymes and in MDA-MB-468 and MCF-10A cells.
Microsomes expressing CYP1A1, CYP1A2, or CYP1B1 and
NADPH reductase were incubated with eupatorin for 20 min-
utes with NADPH as a co-factor. Eupatorin was metabolised
to a large extent by CYP1A1 and CYP1A2 (Figure 3a). The
concentration of the parent compound decreased considera-
bly following incubation with these enzymes, over the 20-
minute period, compared with control microsomes that did not
contain CYPs. In contrast, CYP1B1 was a weak metaboliser
of eupatorin compared with the other two CYP1s (Figure 3a).
After incubation with eupatorin, CYP1B1 produced one
metabolite, assigned E1, which eluted at approximately 9.6
minutes in the HPLC assay used in this study (Figure 4a).
CYP1A1 and CYP1A2 produced three metabolites, assigned
E1, E2, and E3, including the one seen in the case of
Figure 2
CYP1 enzyme expression in MDA-MB-468 and MCF-10A cells. (a) 
EROD activity of MDA-MB-468 and MCF-10A cells. Cells were seeded 
at a density of 5 × 104 cells per millilitre in 24-well plates and left to 
grow for 48 hours. EROD activity was measured as described in Mate-
rials and methods. Error bars represent mean ± standard deviation for n 
= 4 determinations. (b) Selective and inducible CYP1A and CYP1B1 
expression in MDA-MB-468 cells. Lysates were probed with anti-
CYP1A and anti-CYP1B1 antibodies from Gentest Corporation (now 
part of BD Biosciences) and Auvation Limited. Lane 1: Recombinant 
CYP1A1 (top, 0.2 μg) or CYP1B1 (bottom, 0.4 μg) used as positive 
control. Lane 2: MDA-MB-468 cells. Lane 3: MDA-MB-468 cells 
treated with 10 nM TCDD for 24 hours. Lane 4: MCF-10A cells. Exper-
iments were performed in duplicate. EROD, ethoxyresorufin-O-deethyl-
ase; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.Page 5 of 12
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compared with E1 (Figure 4b). All metabolites eluted at reten-
tion times shorter than that corresponding to the parent com-
pound. This indicates that they resulted from hydroxylation/
demethylation of eupatorin catalysed by the cytochrome
P450-reductase system, thereby becoming more polar than
eupatorin.
The metabolite eluting at 9.6 minutes was identified as cirsiliol
after comparison with a reference standard (Figure 4c) and
was the major conversion product of the metabolism of eupa-
torin by CYP1A1 and CYP1A2 (Figures 3b and 4a). In addi-
tion, co-elution studies in which a CYP1B1 incubate of
eupatorin was spiked with a small concentration of cirsiliol
were performed. This resulted in an increase of the total con-
centration of cirsiliol in the sample (Figure 4c). The same iden-
tification pattern was observed when CYP1A1 was spiked
with cirsiliol (data not shown). The metabolites E2 and E3
could not be identified since their authentic standards were
not commercially available.
Having shown that eupatorin is converted to cirsiliol by CYP1
family enzymes in microsomal enzyme assays, we conducted
cellular assays to find out whether the same or a similar bio-
conversions occurred. MDA-MB-468 and MCF-10A cells
were treated with 10 μM eupatorin for 45 minutes and the
samples were analysed with HPLC. Cirsiliol and metabolite E3
could be detected in the MDA-MB-468 cell incubate, but in
small quantities compared with the CYP1A1 and CYP1A2
Figure 3
Rate of metabolism of eupatorin (10 μM) by recombinant microsomes expressing CYP1A1, CYP1A2, or CYP1B1
expressing CYP1A1, CYP1A2, or CYP1B1. (a) Disappearance of 
eupatorin over time by CYP1 family enzymes. (b) Formation of the 
metabolite cirsiliol over a 20-minute time period. Experiments were per-
formed in duplicate as described in Materials and methods. Error bars 
represent mean ± minimum or maximum values for n = 2 
determinations.
Figure 4
Metabolic profile of eupatorin (10 μM) metabolism by CYP1 family enzymes and id ntification of cirsiliol as the primary metabolite
enzymes and identification of cirsiliol as the primary metabolite. (a) Typ-
ical high-pressure liquid chromatography (HPLC) traces of 20-minute 
incubation of CYP1 enzymes with eupatorin. (b) Expansion of (a) 
showing metabolites E2 and E3. (c) Co-elution studies of eupatorin 
with cirsiliol. A 20-minute CYP1B1 incubate of eupatorin was spiked 
with cirsiliol (0.2 μM). Reaction mixtures contained eupatorin, NADPH 
(nicotinamide adenine dinucleotide phosphate), and recombinant 
microsomes purchased from Gentest Corporation (now part of BD Bio-
sciences). Reactions were terminated by the addition of 1% acetic acid 
in methanol. (d) HPLC trace of metabolism of eupatorin in MDA-MB-
468 cells. Samples were analysed by HPLC using a UV detector at 
350 nm. Experiments were performed in triplicate. A350: absorption of 
light at wavelength 350 nm. AU: arbitrary units.Page 6 of 12
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metabolites were observed in MCF-10A cells (Figure 4d).
Thus, the metabolism of eupatorin in MDA-MB-468 cells
matched the CYP1A1 enzyme-catalysed metabolism (com-
paring Figures 4a and 4d).
Eupatorin causes G2/M arrest in MDA-MB-468 cells, as a 
result of CYP1 family enzyme metabolism, and does not 
inhibit the cell cycle of MCF-10A cells
Flow cytometry was used to study the effect of eupatorin on
the cell cycle of MDA-MB-468 and MCF-10A cells. The pur-
pose of the experiments was to provide more insight into the
mechanism of action of the antiproliferative effect of eupatorin
and how this could be related to the CYP1 enzyme-mediated
metabolism. In addition, we wanted to identify which of the
metabolites is mainly responsible for the potency of eupatorin
observed in MDA-MB-468 cells. Cells were treated with 10
μM eupatorin for 30 hours, which resulted in a block in the G2/
M phase of the cell cycle compared with control cells treated
with 0.1% DMSO (Figure 5a). This effect was more profound
in the 48-hour period, during which approximately 70% of the
cells accumulated in the G2/M phase (Figure 5b). Further-
Figure 5
Eupatorin causes G2/M arrest in MDA-MB-468 cells, whereas this effect is not observed in MCF-10A cells. (a) Flow cytometric DNA analysis of 
MDA-MB-468 and MCF-10A cells treated with 10 μM eupatorin. (b) Percentage of MDA-MB-468 cells in G1, S+G2/M, and sub-G1 phases of the 
cell cycle. Cells were plated in 24-well plates and left to grow for 48 hours. Eupatorin was incubated with the cells for 30 and 48 hours, and 0.1% 
dimethylsulfoxide was used as a control. The cells were stained with propidium iodide and analysed using a Beckman Coulter flow cytometer as 
described in Materials and methods. Error bars represent mean ± standard deviation for n = 3 determinations.Page 7 of 12
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from 30 to 48 hours, as is shown by the sub-G1 peak (Figure
5a,b). However, this effect was negligible compared with the
G2/M block. To prove that the cell cycle arrest was due to
metabolism of eupatorin by CYP1 enzymes, we co-treated
MDA-MB-468 cells with 10 μM of the compound and 1.5 μM
acacetin for 48 hours. Acacetin (1.5 μM) reversed the popula-
tion of MDA-MB-468 cells arrested in G2/M from 70% to 40%
but failed to completely return the cell cycle to the initial form
observed in the control sample (Figure 6a). Acacetin (3 μM)
showed a similar effect (data not shown). Acacetin also failed
to correct the phenomenon of apoptosis noticed after treat-
ment of MDA-MB-468 cells with eupatorin. In MCF-10A cells,
eupatorin did not cause cell cycle arrest (Figure 5a). However,
a small fraction of the cells had undergone apoptosis after 30
hours (5% of cells) and 48 hours (6% of cells) (Figure 5a).
Thus, apoptosis was an intrinsic effect of the compound and
did not result from CYP1 family enzyme metabolism.
Eupatorin caused G2/M arrest in MDA-MB-468 cells, and the
effect could be reversed by co-incubation with the CYP1
inhibitor acacetin. Thus, the G2/M arrest must have been due
to CYP1-mediated metabolism, but which of the metabolites
was responsible for this effect remained unknown. Since cirsi-
liol was the only metabolite that had been identified in our anal-
ysis, we treated MDA-MB-468 cells with this compound for 30
and 48 hours and then examined the cell cycle by using flow
cytometry. Cirsiliol also caused G2/M arrest of MDA-MB-468
cells after 48 hours (Figure 6b). However, the effect was not
as dramatic as that observed with eupatorin. The percentage
of cells in G2/M increased from 24% in control to 39% in cir-
siliol-treated MDA-MB-468 cells.
Discussion
The flavonoids are widely recognised as a class of natural
products with cancer-protective properties. In the present
study, it is shown that the flavone eupatorin strongly inhibits
proliferation of MDA-MB-468 cells at submicromolar concen-
trations as a result of CYP1 family enzyme metabolism, which
suggests that it may be a candidate chemopreventative com-
pound toward breast cancer cells that express CYP1
enzymes. Importantly, we found that eupatorin was non-toxic in
human normal breast MCF-10A cells at low concentrations,
and it was only at the highest concentrations (>10 μM) that
cell viability was affected.
The differential expression of cytochrome P450s such as
CYP1B1 protein in breast tumour samples, as opposed to nor-
mal tissue, has been proposed as a target for cancer chemo-
therapy. However, there are often difficulties associated with
relating protein expression to functional activity of CYP1A1
and CYP1B1 [16], and to our knowledge there is no direct
conventional assay that can differentiate between the activities
of these two enzymes. According to our data, MDA-MB-468
cells expressed both enzymes at the protein level. CYP1B1
protein was detected at very low levels, whereas CYP1A1 pro-
tein expression was much stronger. Their expression was also
upregulated following treatment with the CYP1 inducer
TCDD. MDA-MB-468 cells have previously been used to
examine the effects of the antitumour agent DF203 on the reg-
Figure 6
G2/M arrest of MDA-MB-468 caused by eupatorin is due in part to metabolism to cirsiliol and can be reversed by acacetini  i   i  rt t  etabolis  to cirsiliol and can be reversed by acacetin. (a) Cell cycle analysis of 
MDA-MB-468 cells co-treated with 10 μM eupatorin and 1.5 μM acacetin for 48 hours. Histograms are one trace of three independent experiments. 
(b) Cell cycle profile of MDA-MB-468 cells treated with 10 μM cirsiliol for 48 hours. The experiment was performed in duplicate.Page 8 of 12
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Available online http://breast-cancer-research.com/content/10/3/R39ulation of CYP1A1 and CYP1B1 proteins [22]. In that study,
MDA-MB-468 cells were said to constitutively express
CYP1B1, but not CYP1A1, to the protein level by using poly-
clonal rabbit anti-human CYP1B1 and polyclonal antiserum for
human CYP1A1/1A2, respectively [22]. In the present study,
we could not detect any cross-reaction of the CYP1A1 anti-
bodies we used with CYP1B1-containing microsomes (data
not shown). It is possible that the CYP1A1 antibody used in
the study of Chua and colleagues [22] was not specific
enough to detect the desired protein. Importantly, MCF-10A
cells expressed neither CYP1A nor CYP1B1 at the protein
level.
MDA-MB-468 cells constitutively express CYP1A1 enzymes
in their active form. Some authors have reported that the estro-
gen receptor-negative breast cancer cell line MDA-MB-468
expresses CYP1A1 active protein only after treatment with the
CYP1 inducer TCDD [23]. However, low levels of CYP1B1
and CYP1A1 activity have been reported for similar breast
cancer cell lines such as MDA-MB-436, MDA-MB-231, MDA-
MB-157, and T47 in the absence of TCDD, whereas in its
presence the activity was largely augmented [24]. According
to our results, MDA-MB-468 cells expressed active CYP1A1
in the absence of an inducer. The activity was considerably
high compared with the normal breast cell line MCF-10A but
was about three orders of magnitude less than that of MCF-7
cells induced with 10 nM TCDD for 24 hours (data not
shown). Hence, MDA-MB-468 can be used as a model cell
line to test the possible bioactivation of xenobiotics by
CYP1A1. It should be noted, however, that after induction
CYP1B1 activity may also play a role in cell metabolism.
CYP1A1 has been involved in the activation of two main chem-
otherapeutic agents in breast cancer cell lines. In the human
breast adinocarcinoma cell line MCF-7, the anticancer com-
pound DF203 induces CYP1A1 expression. In turn, the
enzyme activates its inducer to a more cytotoxic product,
which results in a remarkable IC50 of 10 nM under these
conditions [22]. However, when the CYP1 inhibitor α-naptho-
flavone [25] is co-incubated with the drug, the IC50 is greater
than 100 μM in MCF-7 cells. Aminoflavone is an antitumour
drug that acts in a similar way [26]. Again, CYP1A1 is respon-
sible for its activation. This agent has astonishing IC50 values
of 0.1 nM in MCF-7 cells and 600 nM in AHR100 cells, an AhR-
deficient variant of MCF-7 cells, where the enzyme CYP1A1 is
not induced [26]. Unlike the abovementioned compounds,
which show activation factors of greater than 1,000, eupatorin
had only a 30-fold difference in IC50 when it was co-incubated
with the CYP1 inhibitor acacetin. This demonstrates that it
would be more effective as a chemopreventative rather than as
a chemotherapeutic drug. Regardless of the difference in
activity, our study reinforces the pivotal role of CYP1 enzymes
and mainly CYP1A1 in breast cancer prevention and therapy
through the activation of xenobiotics.
A recent study examined the antitumour activity of a new series
of fluoro-, methoxyl-, and amino-substituted isoflavones in
human breast MDA-MB-468 and MCF-7 cells as well as two
colon cancer cell lines [27]. The authors reported that MDA-
MB-468 cells were the most sensitive overall, and significant
potentiation of growth inhibitory activity (GI50 < 1 μM) was
observed for some of these compounds when MDA-MB-468
cells were co-incubated with the CYP1A1 inducer TBDD
(2,3,7,8-tetrabromo dibenzo-p-dioxin), which suggests a pos-
sible CYP1A1 bioactivation of the isoflavone derivatives [27].
Eupatorin has been shown to inhibit proliferation of human
gastric adenocarcinoma (MK-1), human uterus carcinoma
(HeLa), and murine melanoma (B16F10) cell lines [6]. How-
ever, in the literature, there is no additional information regard-
ing the antiproliferative mechanism of action of this compound.
In the present study, the antiproliferative activity of eupatorin
found in MDA-MB-468 cells is attributed to a large extent to its
metabolism by the CYP1 family enzymes. First, we observed
that the CYP1 enzyme inhibitor acacetin considerably
increased the IC50 of eupatorin in MDA-MB-468 cells. Sec-
ond, all CYP1 enzymes metabolised eupatorin to cirsiliol, and
CYP1A1 and CYP1A2 metabolised it to another two uniden-
tified metabolites, as shown in the microsomal enzyme assay
system. Moreover, in MDA-MB-468 cells, eupatorin was
metabolised to cirsiliol and the metabolite E3, whereas no
metabolism could be detected in MCF-10A cells.
Cirsiliol, or 3',4'-dihydroxy-5,6,7-trimethoxy flavone (Figure 7),
results from 4'-demethylation of eupatorin. The IC50 values for
cirsiliol in MDA-MB-468 and MCF-10A cells show a 7-fold dif-
ference (Figure 1d), which indicates that CYP1-mediated
metabolism further activates this compound. Nevertheless,
this initial eupatorin metabolite is at least partially responsible
for its antiproliferative activity as it showed lower IC50 values in
MCF-10A cells than eupatorin did. In addition, the metabolites
E2 and E3 contribute to the ultimate submicromolar toxicity of
eupatorin in MDA-MB-468 cells, which was not observed for
cirsiliol. The unidentified metabolites E2 and E3 may be
produced by hydroxylation reactions at positions 5' of the B
ring and 8' of the A ring or by demethylation reactions at posi-
tions 6' and 7' of the A ring (Figure 7).
We have not been able to find any reports on CYP1-mediated
or other cytochrome P450-mediated metabolism of eupatorin.
However, cirsiliol was found to be 3-fold and 5-fold more
active than eupatorin in MK-1 and B16F10 cells, respectively
[6]. Thus, substitution of the 4'-OCH3 to the 4'-OH group in
the B ring of eupatorin dramatically alters its antiproliferative
activity. In addition, there is increasing evidence that flavones
structurally similar to eupatorin are substrates for CYP1
enzymes. Previous studies have underlined the importance of
4'-OCH3 demethylation by CYP1A1, CYP1A2, and CYP1B1
as the main metabolic route of flavones and flavonols contain-
ing one methoxy group [21,28,29]. This type of conversion hasPage 9 of 12
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expected to have greater biological activity than the parent
compound. A recent study has demonstrated that hydroxyla-
tion of the isoflavone genistein in MCF-7 cells as a result of
CYP1A1- and CYP1B1-mediated metabolism can enhance its
antiproliferative properties [18]. Our results agree with the
above findings.
In combination with HPLC analysis of CYP1 enzyme metabo-
lism and cytotoxic assays of eupatorin, flow cytometry demon-
strated that eupatorin arrests MDA-MB-468 cells in the G2/M
phase of the cell cycle as a result of cytochrome P450 metab-
olism. Cirsiliol is a primary product but is not entirely responsi-
ble for this effect since it produced only a moderate inhibition
of the cell cycle at G2/M. Thus, the profound effect of eupa-
torin in MDA-MB-468 cells has to be attributed to all of its
metabolites. Some flavonoids with a structure similar to eupa-
torin are known to have antimitotic activity. For example, 5,3'-
dihydroxy-3,6,7,8,4'-pentamethoxy flavone inhibits tubulin
polymerisation [30]. Casticin, or 5 hydroxy 4', 3,6,7-tetrameth-
oxy flavone, has also been shown to disrupt mitotic spindle
morphology of human KB carcinoma cells [31]. A recent study
has underlined that the 3-hydroxy-4-methoxy groups of the B
ring in synthetic chalcones (which are equivalent to the 3' and
Figure 7
Chemical structures of eupatorin and cirsiliol and possible structures of the metabolites E2 and E3.Page 10 of 12
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ing the binding to the colchicine site in tubulin [32]. Metabo-
lism of eupatorin by CYP1A1 and CYP1B1 might create 3',4'-
dihydroxy or 3'-hydroxy-4'-methoxy groups in positions that will
strongly bind to the colchine-binding site in tubulin and inhibit
mitotic spindle formation. Further studies are required to con-
firm this hypothesis.
In conclusion, the results presented in this study provide more
evidence about the potential of the cytochromes P450
CYP1A1 and CYP1B1 as targets in cancer therapy and pre-
vention. CYP1-catalysed hydroxylation of the natural product
eupatorin in breast cancer cells results in bioactivation to cyto-
static, and possibly antimitotic, agents. Importantly, this proc-
ess has no effect on normal breast cells, which do not express
CYP1 enzymes. Eupatorin is shown by this to be a promising
chemopreventative candidate because of its selective bioacti-
vation in tumour cells which and should be further evaluated by
in vitro mechanistic assays and in vivo studies.
Conclusion
In summary, this study reports the first preliminary evidence on
the antiproliferative mechanism of action of the natural flavone
eupatorin on human breast carcinoma cells. The compound is
shown to be selective toward the tumour cells, and its cell
growth-inhibiting activity is attributed to CYP1 family-mediated
metabolism.
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